Interaction Between Nalbuphine and Morphine in PCA

Sponsor

National Taiwan University Hospital (Other)

Overall Status

Unknown status

CT.gov ID

NCT00155233

Collaborator

(none)

200

Enrollment

Location

Study Details

Study Description

Brief Summary

Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist
This study was designed to investigate the interaction between nalbuphine and morphine

Condition or Disease	Intervention/Treatment	Phase
Postoperative Pain	Drug: Nalbuphine and morphine	Phase 4

Detailed Description

Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist
This study was designed to investigate the interaction between nalbuphine and morphine
The analgesic effect and opioid-related side effects will be investigated

Study Design

Study Type:

Interventional

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double

Primary Purpose:

Treatment

Official Title:

Interaction Between Nalbuphine and Morphine in Postoperative PCA for Gynecologic Patients

Study Start Date :

Jan 1, 2005

Outcome Measures

Primary Outcome Measures

analgesic effect []

Secondary Outcome Measures

incidence of opioid-related side effects []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Age 18-65 y/o
Female patients of ASA physical status I to III
Scheduled for elective abdominal hysterectomy, myomectomy, or excision of ovarian tumor

Exclusion Criteria:

Patients with a definite diagnosis of chronic pain syndrome, psychiatric disorders, or drug abuse (include opioids, NSAIDs, sedatives, antidepressants)
Intraoperative fentanyl use > 3 μg/kg
Patients with definite diagnosis of esophageal reflux syndrome
Use of sedatives, antiemetics, or antipruritics within 24 hours before operation
Surgery > 4 hours or laparoscopy surgery